Subscribe to RSS
DOI: 10.1055/s-2004-832923
Use of Diagnostic Testing for Managing Hepatitis C Virus Infection
Publication History
Publication Date:
02 September 2004 (online)
Serological and virological testing for the hepatitis C virus (HCV) is essential in the management of patients with chronic HCV infection. Recent advances in molecular virology tests and the development of a new international unit standard have greatly simplified the use and interpretation of these tests. In the absence of treatment, baseline serum HCV RNA does not change over time and does not correlate with the severity of hepatic inflammation or fibrosis on liver biopsy. In contrast, changes in serum HCV RNA level are important predictors of virological response to treatment with pegylated interferon and ribavirin.
KEYWORDS
Hepatitis C - diagnosis - polymerase chain reaction - enzyme-linked immunoabsorbent assay - branched-chain DNA assay
REFERENCES
- 1 Choo Q L, Kuo G, Weiner A J et al.. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244 359-362
- 2 Kuo G, Choo Q L, Alter H J et al.. An assay for circulating antibodies to the major etiologic virus of human non-A, non-B hepatitis. Science. 1989; 244 362-364
- 3 Alter H J, Purcell R H, Shih J W et al.. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989; 321 1494-1500
- 4 Gretch D R. Use and interpretation of HCV diagnostic tests in the clinical setting. Clin Liver Dis. 1977; 1 543-557
- 5 Zaaijer H L, Cuypers H T, Reesink H W et al.. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet. 1993; 341 722-724
- 6 Saldanha J, Lelie N, Heath A. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO collaborative study group. Vox Sang. 1999; 76 149-158
- 7 Simmonds P. Variability of hepatitis C virus. Hepatology. 1995; 21 570-583
- 8 Fried M W, Hadziannis S. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin Liver Dis. 2004; 24(suppl 2) 47-54
- 9 Schiff E R, de Medina M, Kahn R S. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis. 1999; 19 3-15
- 10 Gretch D R. Diagnostic tests for hepatitis C. Hepatology. 1997; 26(suppl) 43S-47S
- 11 Kao J H, Lai M Y, Hwang Y T et al.. Chronic hepatitis C without anti-hepatitis C antibodies by second-generation assay: a clinicopathologic study and demonstration of the usefulness of a third-generation assay. Dig Dis Sci. 1996; 41 161-165
- 12 Barrera J, Prancis B, Ercilla G et al.. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang. 1995; 68 15-18
- 13 Fried M W, Draguesku J O, Shindo M et al.. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci. 1993; 38 631-636
- 14 Alter M J. The epidemiology of acute and chronic hepatitis C. Clin Liver Dis. 1997; 1 559-568
- 15 Thio C L, Nolt K R, Astemborski J et al.. Screening for hepatitis C virus in human immunodeficiency virus -infected individuals. J Clin Microbiol. 2000; 38 575-577
- 16 Colin C, Lanoir D, Touzet S et al.. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat. 2001; 8 87-95
- 17 Pawlotsky J M. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis. 2003; 7 127-137
- 18 Alter H J, Tegtmeier G, Jett B et al.. The use of recombinant immunoblot assay in the interpretation of anti-hepatitis C virus reactivity among prospectively followed patients, implicated donors and random donors. Transfusion. 1991; 31 771-776
- 19 Evans C, Tobler L, Polito A et al.. Comparative evaluations of supplemental hepatitis C virus antibody test systems. Transfusion. 1992; 32 408-414
- 20 Bouvier-Alias M, Patel K, Dahari H et al.. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology. 2002; 36 211-218
- 21 Lagging L M, Garcia C E, Westin J et al.. Comparison of serum hepatits C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time. J Clin Microbiol. 2002; 40 4224-4229
- 22 Vellion P, Payan C, Picchio G et al.. Comparative evaluation of the total hepatits C virus core antigen, branched-DNA, and Amplicor monitor assays in determining viremia for patients with chronic hepatits C during interferon plus ribavirin combination therapy. J Clin Microbiol. 2003; 41 3212-3220
- 23 Sarrazin C. Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. J Clin Virol. 2002; 25(Suppl 3) S23-S29
- 24 Pawlotsky J M. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002; 122 1554-1568
- 25 Zaaijer H L, Cuypers H T, Reesink H W et al.. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet. 1993; 341 722-724
- 26 Nolte F S, Fried M W, Shiffman M L et al.. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol. 2001; 39 4005-4012
- 27 Komurian-Pradel F, Paranhos-Baccala G, Sodoyer M et al.. Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods. 2001; 95 111-119
- 28 Kleiber J, Walter T, Haberhausen G et al.. Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA. J Mol Diagn. 2000; 2 158-166
- 29 Kawai S, Yokosuka O, Kanda T et al.. Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay. J Med Virol. 1999; 58 121-126
- 30 Hendricks D A, Friesenhahn M, Tanimoto L et al.. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol. 2003; 41 651-656
- 31 Hill C S. Molecular diagnostic testing for infectious diseases using TMA technology. Expert Rev Mol Diagn. 2001; 1 445-455
- 32 Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription mediated amplification in patients with complete virologic response according to polymerase chain reaction-based asays. Hepatology. 2000; 32 818-823
- 33 Urdea M S, Horn T, Fultz T J et al.. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser. 1991; 24 197-200
- 34 Pawlotsky J M, Martinot-Peignoux M, Poveda J D et al.. Quantification of hepatitis C RNA in serum by branched chain DNA-based signal amplification assays. J Virol Methods. 1999; 79 227-235
- 35 Fang J WS, Chow V, Lau J NY. Virology of hepatitis C virus. Clin Liver Dis. 1997; 1 493-514
- 36 Stuyver L, Wyseur A, van Arnhem W et al.. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypable samples. Virus Res. 1995; 38 137-157
- 37 Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol. 1996; 34 2259-2266
- 38 Zheng X, Pang M, Chan A et al.. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J Clin Virol. 2003; 28 214-216
- 39 Anderson J C, Simonetti J, Fisher D G et al.. Comparison of different HCV viral load and genotyping assays. J Clin Virol. 2003; 28 27-37
- 40 Nakao T, Enomoto N, Takada N, Takada A, Date T. Typing of hepatitis C virus genomes by restriction fragment length polymorphism. J Gen Virol. 1991; 72 2105-2112
- 41 De Cock L, Vranckx R. Serotyping and genotyping of hepatitis C virus in Belgium. Infection. 2003; 31 92-97
- 42 Pawlotsky J M, Prescott L, Simmonds P et al.. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Micrbiol. 1997; 35 1734-1739
- 43 Pawlotsky J M, Bouvier-Alias M, Hezode C et al.. Standardization of hepatitis C virus RNA quantification. Hepatology. 2000; 32 654-657
- 44 Shiffman M L, Ferreria-Gonzalez A, Reddy K R et al.. Comparison of three commercially available assays for HCVRNA utilizing the international unit standard: Implications for management of patients with chronic hepatitis C virus infection in clinical practice. Am J Gastroenterol. 2003; 98 1159-1166
- 45 Krajden M, Ziermann R, Khan A et al.. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Microbiol. 2002; 40 2903-2907
- 46 Yu M L, Chuang W L, Dai C Y et al.. Clinical evaluation of the automated Cobas Amplicor HCV Monitor test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the Quantiplex HCV Version 2.0 test. J Clin Microbiol. 2000; 38 2933-2939
- 47 Nguyen T, Sedghi-Vaziri A, Wilkes L et al.. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat. 1996; 3 75-78
- 48 Fried M W, Shiffman M L, Reddy K R et al.. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med. 2002; 347 975-982
- 49 Davis G L, Wong J B, McHutchison J G et al.. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003; 38 645-652
- 50 Shiffman M L, Hofmann C M, Thompson E B et al.. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology. 1997; 26 780-785
- 51 Shiffman M L, Hofmann C M, Contos M J et al.. A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders. Gastroenterology. 1999; 117 1164-1172
- 52 Lee S. Histological response to interferon alfa-based therapies in hepatitis C. Semin Liver Dis. 2004; 24(suppl 2) 55-60
- 53 Shiffman M L, Hofmann C M, Thompson E B et al.. Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology. 1997; 26 780-785
- 54 Zeuzem S, Heathcote E J, Shiffman M L et al.. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003; 39 106-111
Mitchell L ShiffmanM.D.
Hepatology Section, Virginia Commonwealth University Health System
Box 980341, Richmond, VA 23298
Email: mshiffma@hsc.vcu.edu